|
A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. Clinical research trials and A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer.. A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. clinical trial. Human subjects often receive the most effective healthcare possible for their A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer.  A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer.
A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer.
For Condition: Colorectal Cancer
Status: No longer recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Diagnosis of primary cancer of the colon or rectum - Must have measurable disease - Must be able to comply with study procedure Exclusion Criteria: - Prior chemotherapy for advanced disease - Pregnancy or lactation - Candidates for surgical resection of one or more metastatic foci - Second primary cancer - Inability to take folic acid or vitamin B12
Total Enrollment:
Location and Contact Information:
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Bellevue, Washington,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Asheville, North Carolina,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Latham, New York,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Portland, Oregon,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
St. George, Utah,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Hendersonville, North Carolina,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Seattle, Washington,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Ogden, Utah,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Winston Salem, North Carolina,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Reading, Pennsylvania,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Kalamazoo, Michigan,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Charleston, South Carolina,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Bend, Oregon,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Pittsburgh, Pennsylvania,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Goldsboro, North Carolina,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Huntsville, Alabama,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Pittsfield, Massachusetts,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Columbus, Ohio,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Philadelphia, Pennsylvania,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Provo, Utah,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Spokane, Washington,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Ivins, Utah,
United States
Additional Information:
Study ID Numbers: 5142;
Study Start Date:
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034619
Other Colorectal Cancer Studies:
1. A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
2. Conventional Care With or Without Specialized Cancer Care in Treating Patients Receiving Chemotherapy
3. Low Literacy Intervention for Colorectal Cancer Screening
4. Phase I Study of SU006668 in Patients With Advanced Solid Tumors
5. Photodynamic Therapy System for Patients with Refractory/Unresponsive Solid Tumors
Related Studies:
Other Colorectal Cancer Clinical Trials
Other New York Clinical Trials
Other Latham Clinical Trials
A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer.
|
|
|
|
|
|
|
|
